Scar-Related Ventricular Tachycardia Carries a Real Sudden Death Risk. Here Is When You Need an ICD Versus Ablation.

The Scene

The following scene is drawn from the composite of patients I have cared for in clinic. All identifying details are changed.

James is 58 years old and had a heart attack six years ago. He is on five medications. His cardiologist told him after the heart attack that his ejection fraction was 35%, and then, after six months on the right medications, it recovered to 48%. He thought he was doing well. He runs three miles a week. He and his wife do not talk about the heart attack much anymore.

On a Thursday evening in September he is sitting on the couch watching the news when his chest lights up with what he can only describe later as an electrical pressure, and his heart begins to beat so fast it does not feel like beating at all. He breaks into a sweat. His wife comes into the room. He says “I don’t feel right.” He is trying to stand when his ICD fires.

The shock itself lasts a fraction of a second. It feels like being hit in the chest with a baseball bat. He sits back down on the couch. His heart is back to a normal rhythm. His wife is crying. He tries to tell her he is fine. He is shaking.

The next morning his cardiologist reviews the ICD log. The device shows a 12-second run of ventricular tachycardia at 220 beats per minute that terminated with a single 40-joule shock. The log also shows that James had had a 5-second run of non-sustained VT two nights before that he had not noticed.

Ventricular tachycardia is the most feared arrhythmia in a patient with structural heart disease: fast, potentially lethal, and capable of arriving without warning. Understanding what VT is, why it happens, and what the evidence supports is the foundation for making rational decisions about ICDs, ablation, and the daily life of a patient who knows the device in their chest could fire again.

What It Is

Ventricular tachycardia is a rapid heart rhythm originating in the ventricles, below the bundle of His, running at a rate of 100 beats per minute or faster. The ventricles, rather than being activated by the normal His-Purkinje system in an organized top-down fashion, are activated by an abnormal electrical focus or reentrant circuit within the ventricular myocardium. The result is a wide-complex tachycardia on ECG: the QRS complexes are broad (greater than 120 ms) and distorted because the electrical activation spreads through ventricular muscle rather than through the rapid specialized conduction system.

The cardinal distinctions:

Sustained vs. non-sustained VT:

• Non-sustained VT (NSVT): Three or more consecutive ventricular beats at 100 bpm or faster, lasting less than 30 seconds and terminating spontaneously. NSVT may be asymptomatic (discovered on Holter monitoring) or symptomatic (palpitations, presyncope). Its significance depends entirely on context: NSVT in a structurally normal heart carries a benign prognosis; NSVT in a patient with a reduced EF and prior MI carries a meaningfully higher risk of sustained VT and sudden death.
• Sustained VT: Lasts 30 seconds or longer, or requires termination (by antiarrhythmic drug, cardioversion, or ICD shock) because of hemodynamic compromise. Sustained VT demands immediate evaluation and management.

Monomorphic vs. polymorphic VT:

• Monomorphic VT: Each beat has the same QRS morphology. This pattern suggests a fixed anatomical substrate: most commonly a reentrant circuit anchored to a scar from a prior myocardial infarction.
• Polymorphic VT: The QRS morphology changes beat to beat. This pattern suggests multiple competing circuits or a changing substrate, most commonly seen in the setting of acute ischemia, electrolyte disturbance, or a channelopathy (long QT, Brugada syndrome). Polymorphic VT can degenerate into ventricular fibrillation.

VT storm: Three or more separate episodes of sustained VT within 24 hours, or VT that is incessant. VT storm is a medical emergency with high in-hospital mortality. It requires intensive management in an experienced center.

Idiopathic VT: VT arising in a structurally normal heart. The most common form is right ventricular outflow tract (RVOT) VT, which typically produces a left bundle branch block morphology with inferior axis. RVOT VT is generally benign and highly curable with catheter ablation. Less common but important: fascicular VT (left ventricular, responds to verapamil).

The Mechanism

Scar-Mediated Reentry

The dominant mechanism of sustained monomorphic VT in patients with structural heart disease is scar-mediated reentry. After a myocardial infarction, dead myocardium is replaced by fibrotic scar tissue. The scar itself does not conduct electricity, but the border zone between scar and viable myocardium contains islands and channels of surviving myocardium interspersed with fibrosis. These channels conduct slowly. A reentrant circuit forms when an impulse enters a channel, conducts slowly through it (which allows the surrounding myocardium time to recover), exits the channel, activates the surrounding ventricle, and then re-enters the channel to repeat the cycle 5 / Solid .

The clinical implication is precise: the circuit has a specific anatomical location within the scar. Catheter ablation targeting the critical isthmus of that circuit can permanently interrupt VT without affecting normal cardiac function. This is the basis of VT ablation: find the channel, ablate the channel.

The scar substrate does not form only from MI. Dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy, sarcoidosis, and Chagas disease all create fibrotic substrates that can host VT circuits. The location and morphology of the scar determines the ECG morphology of the VT.

Triggered Activity and Automaticity

Not all VT arises from reentry. Triggered activity (caused by abnormal calcium handling producing afterdepolarizations) drives many forms of VT in the setting of heart failure, digitalis toxicity, and long QT syndrome. Abnormal automaticity (spontaneous phase 4 depolarization in a diseased Purkinje fiber or ventricular myocyte) can produce VT in the setting of ischemia, reperfusion, or catecholamine excess. The distinction between reentry, triggered activity, and automaticity matters for ablation strategy and pharmacologic targeting.

The Relationship Between EF and VT Risk

The risk of sustained VT and sudden cardiac death is strongly predicted by left ventricular ejection fraction. In patients with prior MI:

• EF above 40%: relatively low VT risk
• EF 35-40%: borderline; risk stratification requires additional testing
• EF below 35%: significantly increased risk; ICD implantation is indicated for primary prevention per SCD-HeFT criteria 5 / Solid

The 40-day rule applies after an acute MI: the EF immediately after MI reflects acute myocardial stunning and does not predict long-term VT risk. Current ACC/AHA guidelines recommend reassessing EF at 40-90 days after MI before making ICD decisions, during which time beta-blockers and ACE inhibitors may allow EF recovery 5 / Solid .

How We Diagnose

The Wide-Complex Tachycardia Problem

When a patient presents with a wide-complex tachycardia (rapid heart rhythm with QRS broader than 120 ms), the differential includes VT, SVT with aberrant conduction (rate-related or pre-existing bundle branch block), and pre-excited SVT (as in WPW). The correct diagnosis determines management: treating SVT with aberrant conduction as VT is safe; treating VT as SVT and giving AV-nodal blockers (verapamil, diltiazem) can cause catastrophic hemodynamic deterioration in a patient already compromised by VT.

The Brugada criteria: A decision algorithm for distinguishing VT from SVT with aberrancy, based on QRS morphology characteristics 5 / Solid . Key discriminating features: QRS duration greater than 160 ms favors VT; AV dissociation (P-waves marching through at a slower rate than QRS complexes) is pathognomonic for VT when present; concordance of QRS polarity in all precordial leads favors VT.

The clinical rule: In a patient with known structural heart disease (prior MI, cardiomyopathy) who presents with wide-complex tachycardia, assume VT until proven otherwise. The VT diagnosis is correct in approximately 80% of such patients. Treating SVT with aberrancy as VT (with amiodarone or cardioversion) is rarely harmful; treating VT as SVT with verapamil can be fatal.

Electrophysiology Study and Substrate Mapping

For patients with documented or suspected VT who are candidates for ablation or whose VT mechanism needs characterization, an EP study with electroanatomic mapping is performed. High-density contact mapping systems (Biosense Webster CARTO, Abbott EnSite Precision) allow the electrophysiologist to create a three-dimensional voltage map of the ventricle, identifying scar regions (low-voltage areas) and viable border zones where VT circuits reside. During substrate mapping, the VT circuit’s critical isthmus can be identified even in patients whose VT cannot be induced or sustained long enough to map during tachycardia.

ICD Memory and Intracardiac Electrograms

In patients with implanted ICDs, the device’s stored electrograms and episode log provide the most reliable VT documentation available. Every ICD therapy episode (shock or anti-tachycardia pacing) is logged with the intracardiac electrogram showing the rhythm before, during, and after therapy. This is the gold standard for determining whether device therapy was appropriate (for true VT or VF) or inappropriate (for SVT, T-wave oversensing, or artifact). Device interrogation at clinical follow-up visits recovers this information.

The Evidence

SCD-HeFT: The ICD for Primary Prevention

SCD-HeFT (Bardy GH, et al. N Engl J Med. 2005; DOI: 10.1056/NEJMoa043399): The defining primary prevention ICD trial. Enrolled 2,521 patients with NYHA class II or III heart failure and LVEF of 35% or less, from ischemic or non-ischemic cardiomyopathy. Randomized to placebo, amiodarone, or a shock-only ICD. Primary outcome: all-cause mortality. At 45.5 months median follow-up, the ICD arm had a 23% relative risk reduction in mortality (HR 0.77, 95% CI 0.62-0.96, p=0.007) 5 / Solid . Amiodarone showed no mortality benefit over placebo. The absolute mortality reduction was 7.2% over 5 years (NNT approximately 14 patients treated for 5 years to prevent one death). SCD-HeFT established the ICD as the standard of care for primary prevention of sudden cardiac death in patients with reduced EF heart failure.

MADIT-II (Moss AJ, et al. N Engl J Med. 2002; DOI: 10.1056/NEJMoa013088): Enrolled 1,232 patients with prior MI and LVEF of 30% or less, without requiring non-sustained VT on Holter (unlike the earlier MADIT-I). ICD reduced all-cause mortality (HR 0.69, 95% CI 0.51-0.93, p=0.016) 5 / Solid . The NNT was approximately 11 over 20 months of follow-up in a high-risk population.

What the primary prevention ICD trials did not show: the benefit is concentrated in patients with mildly symptomatic heart failure (NYHA class II-III). Patients with NYHA class IV (advanced heart failure on maximal therapy, very low life expectancy) did not clearly benefit in post-hoc analyses and may not benefit from ICD therapy alone.

VANISH: Catheter Ablation vs. Escalated Antiarrhythmic Drugs in VT

VANISH (Sapp JL, et al. N Engl J Med. 2016; DOI: 10.1056/NEJMoa1510765): Enrolled 259 patients with ischemic cardiomyopathy and VT despite antiarrhythmic drug therapy (most were on amiodarone). Randomized to catheter ablation versus escalated antiarrhythmic drug therapy. Primary outcome: composite of death, VT storm, or ICD shock for VT lasting more than 3 seconds. At 27.9 months median follow-up, ablation was superior to escalated drug therapy (HR 0.72, 95% CI 0.53-0.98, p=0.04) 5 / Solid . The result established catheter ablation as the preferred strategy over escalating amiodarone in patients with recurrent VT on existing therapy.

SMASH-VT (Reddy VY, et al. N Engl J Med. 2007; DOI: 10.1056/NEJMoa065249): Enrolled 128 patients with ischemic cardiomyopathy, ICD implantation, and hemodynamically stable VT or VF. Randomized to prophylactic substrate-based VT ablation versus ICD alone. At 22.5 months, the ablation group had significantly lower rates of appropriate ICD therapy (12% vs 33%, p=0.003) 5 / Solid . This trial supported the concept of performing VT ablation at the time of or shortly after ICD implantation to reduce future shock burden.

Amiodarone: Effective but Toxic

Amiodarone remains the most effective antiarrhythmic drug available for suppressing VT, but its toxicity profile limits long-term use. Pulmonary toxicity (interstitial pneumonitis, potentially irreversible) occurs in 1-5% of patients per year at standard doses. Thyroid effects (hypothyroidism more common, hyperthyroidism more dangerous) occur in 5-15%. Hepatic toxicity, corneal microdeposits, peripheral neuropathy, and photosensitivity are additional concerns. The drug’s very long half-life (up to 100 days) means that toxicity effects persist long after the drug is discontinued 5 / Solid .

Amiodarone is appropriate for acute VT suppression, for patients with VT storm, and for patients who are not candidates for ablation. For long-term VT management in eligible patients, catheter ablation is preferred over lifelong amiodarone.

Sex Differences in VT

Sudden cardiac death, which VT can precipitate, is substantially more common in men than in women at all ages. Women have a lower absolute risk of sustained VT from structural heart disease, in part because coronary artery disease and ischemic cardiomyopathy (the dominant VT substrate) develop a decade later in women than in men 5 / Solid . However, when VT and sudden cardiac death do occur in women, they more commonly arise from non-ischemic cardiomyopathy, long QT syndrome, and Takotsubo cardiomyopathy rather than from ischemic scar.

Women with reduced EF cardiomyopathy derive equal benefit from ICD implantation for primary prevention as men in SCD-HeFT subgroup analyses, but women are historically less likely to be referred for ICD implantation even when they meet the criteria 4 / Promising .

The Patient Experience

Living with an ICD After a VT Event

The week after an ICD fires for VT is, for most patients, among the more psychologically difficult periods of their cardiac care. The fear of recurrence is rational: if the device fired once, the substrate that triggered VT is still present. The shock itself is traumatic: patients consistently describe ICD shocks as severe pain lasting a fraction of a second, followed by a surreal normalization of their heart rhythm and a flood of adrenaline and confusion.

Common psychological sequelae after ICD shock include:

• Hypervigilance about cardiac sensations, difficulty distinguishing normal palpitations from the onset of VT
• Sleep disruption, particularly fear of VT occurring at night (when the patient is relaxed and parasympathetic tone is high, increasing vulnerability to some VT circuits)
• Driving restriction: most states require a period of driving restriction after a sustained VT event treated with ICD shock, typically 3-6 months if VT is suppressed. Patients should be counseled explicitly about this.
• Depression and anxiety: the psychological burden of an ICD shock is substantial; validated tools (TADS scale) document high rates of device-related anxiety in the first year after implant 5 / Solid .

What Your Doctor Will Not Have Time to Explain

1. Non-sustained VT on a Holter does not automatically mean you need an ICD. NSVT in a patient with a normal echocardiogram and no structural heart disease usually requires no specific treatment. NSVT in a patient with reduced EF requires additional risk stratification. Context is everything.

2. Anti-tachycardia pacing (ATP) is a painless treatment your ICD uses first. Most ICDs are programmed to deliver a burst of rapid pacing (ATP) before resorting to a shock. ATP terminates VT in approximately 70-80% of episodes without the patient feeling anything or feeling only a brief fluttering. If your ICD device record shows “ATP delivered,” that is not a shock.

3. VT ablation can substantially reduce future ICD shocks. Catheter ablation does not replace the ICD but can eliminate or dramatically reduce the frequency of VT episodes and ICD therapies. For patients who have received multiple shocks, ablation is a quality-of-life and survival intervention.

4. Amiodarone will require monitoring for lung, thyroid, and liver toxicity. If you are started on amiodarone, ask your cardiologist about the monitoring schedule: chest X-ray and pulmonary function tests at baseline and annually, thyroid function every 3-6 months, liver function every 6 months. This monitoring is not optional.

5. The ICD cannot treat asystole or PEA. An ICD treats VT and VF. If the heart stops in asystole (flat line) or pulseless electrical activity, the device cannot help. Bystander CPR and emergency services remain the treatment for arrest not caused by VT or VF.

Sex Differences in Patient Experience

Women with ICDs and VT report higher rates of ICD shock-related anxiety and lower rates of cardiac rehabilitation participation than men 4 / Promising . The cultural expectation that men endure cardiac illness more stoically (and thus experience less anxiety) is not supported by objective data; rather, both sexes suffer psychologically from ICD shocks, but women are less likely to receive formal psychological support. A referral for device-related anxiety is appropriate for any patient after a significant ICD event, regardless of sex.

Decisions and Trade-Offs

The ICD Decision: Primary Prevention

The decision to implant an ICD for primary prevention of sudden cardiac death is one of the most consequential decisions in cardiology. The evidence-based thresholds:

• LVEF 35% or less, NYHA class II or III heart failure, on guideline-directed medical therapy for at least 3 months: ICD is Class I 5 / Solid
• Prior MI with LVEF 40% or less and inducible VT on EP study: ICD is Class I 5 / Solid
• The 40-day and 3-month rules: ICD decisions should not be made within 40 days of an acute MI or within 3 months of initiating new heart failure medication, because EF may improve with treatment

What must be included in the primary prevention ICD conversation:

• The absolute mortality benefit over the relevant time horizon (approximately 7% over 5 years in SCD-HeFT)
• The inappropriate shock risk: approximately 15-20% of ICD patients receive at least one inappropriate shock (for SVT, oversensing) in the first 5 years. Programming to minimize inappropriate therapy is important.
• The device infection risk: approximately 1-2% lifetime risk of pocket infection requiring device extraction
• The psychological burden of living with a device that may fire
• The patient’s values around quality of life versus longevity

The Ablation Decision: Recurrent VT on Medical Therapy

For patients with recurrent VT and ICD shocks despite antiarrhythmic drug therapy, VT catheter ablation is Class I (VANISH data). The procedure-related risk includes cardiac perforation (0.5-1%), stroke (0.5%), and a small risk of acute hemodynamic instability during VT induction. Thirty-day mortality in experienced centers is below 2% in stable patients but higher in those presenting with VT storm (10-15%).

Access to VT ablation requires a high-volume electrophysiology program with specific expertise in substrate mapping and VT management. This expertise is concentrated at academic medical centers: in the Chicago metropolitan area, Northwestern Medicine, Rush University Medical Center, and the University of Chicago. In rural Illinois and the broader Midwest, referral to a regional center for VT ablation is the appropriate path.

Cost

ICD implantation is covered by Medicare and commercial insurers under the established criteria. The device itself costs $25,000-$40,000; total implant episode costs are typically $50,000-$70,000. Annual device management (office visits, device interrogation, battery monitoring) is covered. VT ablation is covered under appropriate documentation.

Three Questions to Ask Your Cardiologist

1. “My ejection fraction is [X]. Given that and my heart failure status, what is my specific estimated risk of sudden cardiac death over the next 5 years, and how much would an ICD reduce that risk in absolute terms?”
2. “If my ICD fires for VT, what is the process for evaluating whether catheter ablation is appropriate for me, and who at your institution or at a referral center performs this procedure?”
3. “What are the top three reasons my ICD might fire inappropriately, and how is my device programmed to minimize that?”

Clinical Synthesis

Ventricular tachycardia is, in most patients, a downstream consequence of structural heart disease that was itself the downstream consequence of risk factors that were present for years before the first cardiac event. The scar that hosts the VT circuit formed during a myocardial infarction. That MI was the downstream consequence of atherosclerosis. The atherosclerosis was downstream of high ApoB, uncontrolled blood pressure, insulin resistance, and physical inactivity. This is the standard atherosclerosis cascade.

Preventing VT begins years before the ICD implant, at the point where the plaque burden is assessed, the ApoB is measured, and the blood pressure is treated seriously rather than “well enough.” SCD-HeFT patients who survived to receive ICD benefit had already reached the end stage of a preventable disease. This clinical framework aims to interrupt the chain earlier.

For patients who already have structural heart disease and are managing VT risk, a structured post-care program provides ongoing structured monitoring, medication improvement reviews, and access to specialist consultation for the multi-medication complexity that characterizes the typical ICD patient.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.